77 related articles for article (PubMed ID: 8555752)
1. Increased cerebral blood flow during m-CPP exacerbation of obsessive-compulsive disorder.
Hollander E; Prohovnik I; Stein DJ
J Neuropsychiatry Clin Neurosci; 1995; 7(4):485-90. PubMed ID: 8555752
[TBL] [Abstract][Full Text] [Related]
2. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
Stein DJ; Van Heerden B; Wessels CJ; Van Kradenburg J; Warwick J; Wasserman HJ
Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug; 23(6):1079-99. PubMed ID: 10621951
[TBL] [Abstract][Full Text] [Related]
3. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
Broocks A; Pigott TA; Hill JL; Canter S; Grady TA; L'Heureux F; Murphy DL
Psychiatry Res; 1998 Jun; 79(1):11-20. PubMed ID: 9676822
[TBL] [Abstract][Full Text] [Related]
4. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
[TBL] [Abstract][Full Text] [Related]
5. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
Gross-Isseroff R; Cohen R; Sasson Y; Voet H; Zohar J
Neuropsychobiology; 2004; 50(3):200-5. PubMed ID: 15365215
[TBL] [Abstract][Full Text] [Related]
6. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
Goodman WK; McDougle CJ; Price LH; Barr LC; Hills OF; Caplik JF; Charney DS; Heninger GR
Biol Psychiatry; 1995 Aug; 38(3):138-49. PubMed ID: 7578657
[TBL] [Abstract][Full Text] [Related]
7. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
[TBL] [Abstract][Full Text] [Related]
8. MR perfusion-weighted imaging and quantitative analysis of cerebral hemodynamics with symptom provocation in unmedicated patients with obsessive-compulsive disorder.
Chen XL; Xie JX; Han HB; Cui YH; Zhang BQ
Neurosci Lett; 2004 Nov; 370(2-3):206-11. PubMed ID: 15488324
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.
Hollander E; Kwon J; Weiller F; Cohen L; Stein DJ; DeCaria C; Liebowitz M; Simeon D
Psychiatry Res; 1998 Jul; 79(3):213-7. PubMed ID: 9704868
[TBL] [Abstract][Full Text] [Related]
10. Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls.
Ho Pian KL; Westenberg HG; den Boer JA; de Bruin WI; van Rijk PP
Biol Psychiatry; 1998 Sep; 44(5):367-70. PubMed ID: 9755360
[TBL] [Abstract][Full Text] [Related]
11. Cerebral activation in children and adolescents with obsessive-compulsive disorder before and after treatment: a functional MRI study.
Lázaro L; Caldú X; Junqué C; Bargalló N; Andrés S; Morer A; Castro-Fornieles J
J Psychiatr Res; 2008 Oct; 42(13):1051-9. PubMed ID: 18261744
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of cerebral blood flow in children with obsessive compulsive disorder and attention deficit hyperactivity disorder].
Oner P; Oner O; Aysev A; Küçük O; Ibiş E
Turk Psikiyatri Derg; 2008; 19(1):13-8. PubMed ID: 18330739
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of obsessive-compulsive disorder.
Klein DF
Encephale; 1990; 16 Spec No():331-4. PubMed ID: 2209491
[TBL] [Abstract][Full Text] [Related]
14. Neurobiology of obsessive compulsive disorder: a possible role for serotonin.
Winslow JT; Insel TR
J Clin Psychiatry; 1990 Aug; 51 Suppl():27-31; discussion 55-8. PubMed ID: 2199432
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychological performance and regional cerebral blood flow in obsessive-compulsive disorder.
Lacerda AL; Dalgalarrondo P; Caetano D; Haas GL; Camargo EE; Keshavan MS
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):657-65. PubMed ID: 12787854
[TBL] [Abstract][Full Text] [Related]
16. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings.
Hollander E; Fay M; Cohen B; Campeas R; Gorman JM; Liebowitz MR
Am J Psychiatry; 1988 Aug; 145(8):1015-7. PubMed ID: 2839998
[TBL] [Abstract][Full Text] [Related]
17. Effects of behavior therapy on regional cerebral blood flow in obsessive-compulsive disorder.
Nakatani E; Nakgawa A; Ohara Y; Goto S; Uozumi N; Iwakiri M; Yamamoto Y; Motomura K; Iikura Y; Yamagami T
Psychiatry Res; 2003 Oct; 124(2):113-20. PubMed ID: 14561429
[TBL] [Abstract][Full Text] [Related]
18. Surface anatomical profile of the cerebral cortex in obsessive-compulsive disorder: a study of cortical thickness, folding and surface area.
Fan Q; Palaniyappan L; Tan L; Wang J; Wang X; Li C; Zhang T; Jiang K; Xiao Z; Liddle PF
Psychol Med; 2013 May; 43(5):1081-91. PubMed ID: 22935427
[TBL] [Abstract][Full Text] [Related]
19. Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD.
Hollander E; Cohen LJ; DeCaria C; Saoud JB; Stein DJ; Cooper TB; Islam NN; Liebowitz MR; Klein DF
Biol Psychiatry; 1993 Sep; 34(6):407-13. PubMed ID: 8218609
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.
Pigott TA; Hill JL; Grady TA; L'Heureux F; Bernstein S; Rubenstein CS; Murphy DL
Biol Psychiatry; 1993 Jan; 33(1):3-14. PubMed ID: 8420593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
